Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

To date, men undergoing screening through the measurement of prostate-specific antigen (PSA) levels have had a significant reduction in neoplastic mortality. Because of its low specificity, however, ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital, and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, ...

Duncan Sutcliffe from Worcester urges men over 50 to request annual PSA tests from their GP, highlighting early prostate cancer detection saves UK lives.